Amicus Therapeutics Inc. (NASDAQ:FOLD) shares were down 6.9% during mid-day trading on Thursday . The stock traded as low as $6.58 and last traded at $6.64, with a volume of 4,349,813 shares. The stock had previously closed at $7.13.

Several research analysts have issued reports on FOLD shares. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research report on Monday, July 25th. Leerink Swann restated an “outperform” rating and issued a $19.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. Chardan Capital lifted their price target on shares of Amicus Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, April 12th. Robert W. Baird started coverage on shares of Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating and a $9.00 price target on the stock. Finally, Bank of America Corp. started coverage on shares of Amicus Therapeutics in a research report on Wednesday, May 18th. They issued a “buy” rating and a $10.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $12.19.

The firm has a 50-day moving average of $5.92 and a 200-day moving average of $6.84. The stock’s market cap is $853.77 million.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.01. On average, equities analysts anticipate that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current year.

In other Amicus Therapeutics news, General Counsel Ellen Rosenberg acquired 15,000 shares of the business’s stock in a transaction that occurred on Thursday, June 2nd. The shares were acquired at an average cost of $7.67 per share, for a total transaction of $115,050.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jay Barth sold 20,916 shares of the stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $7.00, for a total transaction of $146,412.00. Following the completion of the transaction, the insider now owns 25,458 shares in the company, valued at $178,206. The disclosure for this sale can be found here.

Other large investors have recently bought and sold shares of the company. Nationwide Fund Advisors raised its stake in Amicus Therapeutics by 1.7% in the fourth quarter. Nationwide Fund Advisors now owns 105,597 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,754 shares during the period. Swiss National Bank raised its stake in Amicus Therapeutics by 3.8% in the fourth quarter. Swiss National Bank now owns 140,200 shares of the biopharmaceutical company’s stock valued at $1,360,000 after buying an additional 5,100 shares during the period. TD Asset Management Inc. raised its stake in Amicus Therapeutics by 1.5% in the fourth quarter. TD Asset Management Inc. now owns 178,700 shares of the biopharmaceutical company’s stock valued at $1,733,000 after buying an additional 2,600 shares during the period. California Public Employees Retirement System raised its stake in Amicus Therapeutics by 3.7% in the fourth quarter. California Public Employees Retirement System now owns 326,100 shares of the biopharmaceutical company’s stock valued at $3,163,000 after buying an additional 11,600 shares during the period. Finally, ProShare Advisors LLC raised its stake in Amicus Therapeutics by 15.6% in the fourth quarter. ProShare Advisors LLC now owns 117,318 shares of the biopharmaceutical company’s stock valued at $1,138,000 after buying an additional 15,789 shares during the period.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.